Li Shuai, Dong Dezuo, Geng Jianhao, Zhu Xianggao, Shi Chen, Zhang Yangzi, Wang Hongzhi, Zhou Shun, Wu Hao, Cai Yong, Li Yongheng, Wang Weihu
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiation Oncology, Peking University Cancer Hospital and Institute, Beijing, China.
Front Oncol. 2019 Oct 15;9:1080. doi: 10.3389/fonc.2019.01080. eCollection 2019.
To analyze the prognostic factors and optimal response interval for stereotactic body radiotherapy (SBRT) in patients with lung oligometastases (OM) or oligoprogression (OP) from colorectal cancer (CRC). Patients with lung OM or OP from CRC treated by SBRT at our hospital were included in this retrospective review. The local control (LC), response to SBRT in different evaluation interval and regional metastases (RM) was analyzed. The risk factor for LC and RM was calculated using the Kaplan-Meier method and compared using the Log-rank test. Multivariate analysis with a Cox proportional hazards model was used to test independent significance. A total of 53 patients with 105 lung metastases lesions treated from 2012 to 2018 were involved in this retrospective study. The median biologically effective dose (BED) for these patients was 100 Gy (range: 75-131.2 Gy). Complete response (CR) increased from 27 (25.7%) to 46 (43.8%) lesions at 1.8 and 5.3 months following SBRT, and at the last follow-up, 52 (49.5%) lesions achieved CR. The median follow-up duration for all patients was 14 months (range: 5-63 months), and 1-year LC was 90.4%. During the follow-up, 10 lesions suffered local relapse after SBRT (9 of them occurred within 8 months after SBRT). The univariate analysis shows BED ≥ 100 Gy ( = 0.003) and gross tumor volume (GTV) < 1.6 cm ( = 0.011) were better predictors for 1-year LC. The patients with lung oligoprogression had higher 1-year RM when compared with patients with lung oligometastases (hazard ratio 2.78; 95% confidence interval [CI] 1.04-7.48, = 0.042). Until the last follow up, 4 (7.5%) patients suffered grade 2 radiation pneumonitis, and no grade 3-4 toxicity was observed. SBRT provides favorable LC in CRC patients with lung OM or OP, and the GTV and BED can affect the LC. Radiology examinations nearly 5-6 months following SBRT appear to represent the final local effect of SBRT, and the patients with oligoprogression has higher RM.
分析立体定向体部放疗(SBRT)治疗结直肠癌(CRC)肺寡转移(OM)或寡进展(OP)患者的预后因素及最佳反应间隔。本回顾性研究纳入了在我院接受SBRT治疗的CRC肺OM或OP患者。分析局部控制(LC)、不同评估间隔下对SBRT的反应以及区域转移(RM)情况。采用Kaplan-Meier法计算LC和RM的危险因素,并使用Log-rank检验进行比较。使用Cox比例风险模型进行多因素分析以检验独立显著性。本回顾性研究共纳入2012年至2018年期间治疗的53例患者,共105个肺转移病灶。这些患者的中位生物等效剂量(BED)为100 Gy(范围:75 - 131.2 Gy)。SBRT后1.8个月和5.3个月时,完全缓解(CR)的病灶数从27个(25.7%)增至46个(43.8%),在末次随访时,52个(49.5%)病灶达到CR。所有患者的中位随访时间为14个月(范围:5 - 63个月),1年LC率为90.4%。随访期间,10个病灶在SBRT后出现局部复发(其中9个在SBRT后8个月内发生)。单因素分析显示,BED≥100 Gy(P = 0.003)和肿瘤总体积(GTV)<1.6 cm(P = 0.011)是1年LC更好的预测因素。与肺寡转移患者相比,肺寡进展患者的1年RM更高(风险比2.78;95%置信区间[CI] 1.04 - 7.48,P = 0.042)。至末次随访时,4例(7.5%)患者发生2级放射性肺炎,未观察到3 - 4级毒性反应。SBRT为CRC肺OM或OP患者提供了良好的LC,GTV和BED可影响LC。SBRT后近5 - 6个月的影像学检查似乎代表了SBRT的最终局部效果,且寡进展患者的RM更高。